Indian pharmaceutical company, Micro Labs Limited, has acquired 98.88% controlling equity stake in Swiss Pharma Nigeria Limited (“Swipha”), previously held by SERVIER INTERNATIONAL B.V. and Servier Nederland B.V.’s, following their divestment from Nigeria.
Udo Udoma & Belo-Osagie acted as Nigerian counsel to Micro Labs Limited on the Nigerian elements of its acquisition. Duale, Ovia & Alex-Adedipe acted as Nigerian Counsel to Servier International B.V. and its related company in the divestment of their 98.88% controlling equity stake in Swipha. Indian law firm, Avyakta Law acted as Indian legal advisor to Micro Labs Limited.
Swipha, established in 1976, is a leading pharmaceutical company in Nigeria, dedicated to delivering high-quality, affordable medicines to improve healthcare outcomes in Nigeria and across Africa. The company’s portfolio spans essential therapeutic areas, including central nervous system, anti-malaria, anti-infectives, cardiovascular health, and anti-diabetic medications. Notably, Swipha was the first in Nigeria, West, and Central Africa to attain WHO Pre-qualification for Zinc (Anti-Diarrhea) and Sulfadoxine-Pyrimethamine (Anti-Malaria) drugs, underscoring its commitment to quality and accessibility.
Micro Labs, headquartered in India, has a strategic network of 14 formulation plants, including an injectable unit and a bulk drug facility. The company has established international offices in key locations such as the United States, the United Kingdom, Germany, Australia, and Nigeria, with representative offices in emerging markets. In Nigeria, the company operate through its subsidiary MICRONOVA PHARMACEUTICL
.png)
.jpg)
.jpeg)
